Clinical trials: Suppurative Hidradenitis
Hidradenitis Suppurativa
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.
- Trial name
- HS OBTAIN (NCT05849922)
- Testing
- SAR442970
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 86 people
- Sponsor
- Sanofi
Hidradenitis Suppurativa
Hidradenitis Suppurativa Study of Izokibep
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity.
- Trial name
- NCT05905783
- Testing
- Izokibep
- Where
- 98 sites in United States, Canada and 6 more
- Volunteers
- 258 people
- Sponsor
- ACELYRIN Inc.
Hidradenitis Suppurativa
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT03607487
- Testing
- INCB054707
- Where
- 13 sites in Canada, Denmark and 1 more
- Volunteers
- 35 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
Efficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa
- Trial name
- NCT04856930
- Testing
- Imsidolimab
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- Vanda Pharmaceuticals
Hidradenitis Suppurativa
Anakinra as a Treatment for Hydradenitis Suppurativa
This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS).
- Trial name
- NCT01516749
- Testing
- anakinra
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Hidradenitis Suppurativa
Wound Dressings for Hidradenitis Suppurativa
The primary purpose of this research is to determine how the types of wound dressings affect quality of life for people with Hidradenitis Suppurativa (HS).
- Trial name
- NCT04194541
- Testing
- Cutimed Sorbact Hydroactive B wound dressing, Cutimed Siltect wound dressing, Sorbion Sana multi-star wound dressing
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Miami
Hidradenitis Suppurativa (HS)
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100).
- Trial name
- NCT06241573
- Testing
- Spesolimab
- Where
- 36 sites in United States, Argentina and 12 more
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Hidradenitis Suppurativa
A Bioelectric Dressing for Post De-Roofing Treatment of HS
The primary purpose of this study is to test if the use of a bioelectric dressing can improve healing after a surgical procedure called de-roofing.
- Trial name
- NCT05057429
- Testing
- Bioelectric Dressing, Standard Gauze Dressing
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Miami
Hidradenitis Suppurativa
A Study of Bermekimab in Patients With Hidradenitis Suppurativa
Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.
- Trial name
- NCT03512275
- Testing
- Bermekimab Monoclonal Antibody 400 mg
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER (OLE) (NCT01635764)
- Testing
- adalimumab
- Volunteers
- 508 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
Etanercept for Treatment of Hidradenitis
This study is being done to test a drug called etanercept (Enbrel®). Etanercept has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic moderate to severe plaque psoriasis (PsO), for use in…
- Trial name
- NCT00107991
- Testing
- etanercept
- Volunteers
- 15 people
- Sponsor
- University of Pennsylvania
Hidradenitis Suppurativa (Acne Inversa)
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to…
- Trial name
- NCT02421172
- Testing
- CJM112
- Where
- 16 sites in United States, Denmark and 3 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult…
- Trial name
- DETERMINED 1 (NCT03926169)
- Testing
- Risankizumab
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 243 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa, Hidradenitis
Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
To establish the safety of radiotherapy in the treatment of advanced hidradenitis suppurativa. Patients will receive radiotherapy treatment over one week and then they will be followed for the next three months.
- Trial name
- RTHS (NCT03040804)
- Testing
- Low dose Radiotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Montefiore Medical Center
Hidradenitis Suppurativa
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa
- Trial name
- NCT01838499
- Testing
- MEDI8968, Saline
- Where
- 27 sites in United States
- Volunteers
- 224 people
- Sponsor
- AstraZeneca
Hidradenitis Suppurativa, Hidradenitis
HidraWear Study for Hidradenitis Suppurativa Wounds
The product, HidraWear AX (www.hidrawear.com) is and adhesive free wound dressing system for the every day home care of Hidradenitis Suppurativa (HS), a debilitating disease of the skin for which there are limited wound dressing…
- Trial name
- NCT04449354
- Testing
- HidraWear Ax
- Where
- Ireland
- Volunteers
- 16 people
- Sponsor
- HidraMed Solutions Ltd
Acne Inversa
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks.
- Trial name
- NCT04092452
- Testing
- PF-06650833, PF-06700841, PF-06826647
- Where
- 77 sites in United States, Australia and 1 more
- Volunteers
- 194 people
- Sponsor
- Pfizer
Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) Tunneling Wounds
The purpose of this study is to look at the change in the microbiome (bacterial composition) of an HS tunneling wound and examine if treatment with an antibiofilm surfactant wound gel (ABWG) (a topical medication that will fight…
- Trial name
- NCT04648631
- Testing
- antibiofilm surfactant wound gel (ABWG)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Miami
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of moderate to severe hidradenitis suppurativa.
- Trial name
- SHINE (NCT03487276)
- Testing
- IFX-1
- Where
- 41 sites in United States, Bulgaria and 7 more
- Volunteers
- 179 people
- Sponsor
- InflaRx GmbH